Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARGX-110 |
Synonyms | |
Therapy Description |
Cusatuzumab (ARGX-110) is a monoclonal antibody that targets CD70, resulting in inhibition of CD70-CD27-mediated signaling and enhanced immune response against CD70-expressing tumor cells (PMID: 28765328, PMID: 24492296, PMID: 32601337). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARGX-110 | JNJ-74494550|Cusatuzumab | Cusatuzumab (ARGX-110) is a monoclonal antibody that targets CD70, resulting in inhibition of CD70-CD27-mediated signaling and enhanced immune response against CD70-expressing tumor cells (PMID: 28765328, PMID: 24492296, PMID: 32601337). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|